Status:
UNKNOWN
Bone Microstructure After Gastrectomy Evaluating by Using HR-pQCT
Lead Sponsor:
Nagasaki University
Conditions:
Osteoporosis
Sarcopenia
Eligibility:
All Genders
60-79 years
Brief Summary
Osteoporosis after gastrectomy, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after gastrectomy. The aim...
Detailed Description
The patients after gastrectomy loss appetite and decrease the weight. Total gastrectomy especially cause severe sarcopenia and metabolic change. Osteoporosis after gastrectomy, which is characterized ...
Eligibility Criteria
Inclusion
- Planning ESD, DG, or TG due to gastric cancer
- Provide signed informed consent
Exclusion
- pregnancy
- Current use of the following osteoporosis agents; Teriparatide, Denosumab, and bisphosphonate
- Hyperthyroidism
- Hyperparathyroidism
- Present malignancy (except in situ carcinoma)
- Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy
- Other diseases which affect bone metabolism
- Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures
- Received \> 3 months (or equivalent) of osteoporosis treatment
- Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
Key Trial Info
Start Date :
September 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2023
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03398226
Start Date
September 18 2017
End Date
March 31 2023
Last Update
January 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagasaki University Hospital
Nagasaki, Japan, 852-8501